PB 16 of 2026
National Health (February 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026
I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.
Dated 28 January 2026
REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
(1) This instrument is the National Health (February 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026.
(2) This instrument may also be cited as PB 16 of 2026.
2 Commencement
This instrument commences on 1 February 2026.
3 Authority
This instrument is made under sections 99ACD and 99ACR of the National Health Act 1953.
4 Definitions
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
Reduction day refers to 1 February 2026.
5 Brands of pharmaceutical item not subject to a price reduction
- I determine under paragraph 99ACD(7A)(a) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 1 that comes into force on the reduction day is to be equal to the approved ex‑manufacturer price, on the day before the determination day, of the listed brands of the existing item.
6 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply
- I determine under paragraph 99ACR(6)(b) of the Act that the approved ex-manufacturer price of the related brand of the related item specified in column 2 of an item in the table in Schedule 2 is reduced in relation to the reduction day by the percentage specified in column 3 of the table item.
Schedule 1 Brands of pharmaceutical item not subject to a price reduction
Part 1
Column 1 | Column 2 |
Item | Brand of pharmaceutical item |
| Drug | Form | Manner of administration | Brand |
1 | Drospirenone with ethinylestradiol | Pack containing 24 tablets 3 mg drospirenone with 20 micrograms ethinylestradiol and 4 inert tablets | Oral | Brooke |
1 | Drospirenone with ethinylestradiol | Pack containing 21 tablets 3 mg drospirenone with 30 micrograms ethinylestradiol and 7 inert tablets | Oral | Brooklynn |
Schedule 2 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply
Part 1
Column 1 | Column 2 | Column 3 |
Item | Brand of pharmaceutical item | |
| Drug | Form | Manner of administration | Brand | % Reduction |
1 | Aflibercept | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL) | Injection | Eylea | 20% |